Datasets:

jwigginton

/

news-sp500

like 0

ZBRA

Company to showcase the industry’s smallest back-of-hand scanner, new wearable computers and autonomous mobile robots, enabling workers to streamline productivityLINCOLNSHIRE, Ill., March 11, 2024--(BUSINESS WIRE)--Zebra Technologies Corporation (NASDAQ: ZBRA), a leading digital solution provider enabling businesses to intelligently connect data, assets, and people, today announced new enterprise mobile computing and intelligent automation solutions designed to enable an agile, resilient supply chain with the power of a connected workforce. Zebra will highlight its expanded portfolio of solutions at MODEX 2024 Booth B6623 in the Georgia World Congress Center – Hall B, March 11-14 in Atlanta, Ga.Operations leaders in the manufacturing, warehouse, retail, and transportation and logistics industries worldwide continue to grapple with fostering resilient supply chains amid heightened omnichannel demands for speed and accuracy, ongoing labor shortages, and economic uncertainty. Recognizing the criticality of an optimized supply chain, 89% of decision-makers surveyed in Zebra’s 2023 Global Warehouse Study say if their organizations do not invest in technology to improve operations, they will not meet their business objectives."Managing the supply chain has become more complex with increased consumer expectations for inventory and same-day deliveries," said Andre Luecht, Global Strategy Lead, Transportation, Logistics and Warehousing, Zebra Technologies. "Zebra helps businesses work in new ways with technology and automation to drive the right outcomes in their operations and build an agile supply chain through better accuracy, visibility, and efficiency."Connected Frontline Workers Drive ProductivityAccording to Zebra’s study, eight in 10 decision-makers and frontline workers said using more technology and automation would help meet or exceed productivity goals. In addition, decision-makers (54%) and workers (49%) agree addressing worker comfort and ergonomics is a top workforce initiative.Story continuesAt MODEX, visitors will see how Zebra’s new RS2100 wearable scanner – the industry’s smallest back-of-hand (BOH) scanner – enhances productivity and delivers new levels of comfort to workers. The unique mount on the RS2100 leaves the palm completely unobstructed, providing greater freedom to handle items.Zebra will also launch the WT6400 and WT5400 wearable computers. Engineered to streamline hands-free workflows while enhancing comfort, the WT6400 and WT5400 provide more flexibility for picking orders, sorting items, and managing inventory with greater efficiency and accuracy. With a larger display and integrated keyboard, the WT6400 is easily accessible for right- and left-handed workers, and its integrated angled camera captures images to document damaged items or completed tasks. The WT6400 is designed for demanding environments, including freezer operation (-30°C), while the WT5400 introduces a new class of wearable computers for hands-free retail workflows.A new addition to Zebra’s TC5X series are the TC53e/TC58e/TC53e-RFID mobile computers. Designed to meet today’s latest standards, the TC5Xe series offers 5G, Wi-Fi 6E, integrated RFID, premium security features and contains 25% post-consumer recycled plastic by mass. The TC53e-RFID offers integrated short-range UHF RFID, enabling associates to take inventory in the backroom, validate tickets at a concert or verify all items in a shopping cart from up to nearly 4 ft/1.2m away with the same device ergonomics as the standard TC53e.The TC5Xe series, WT6400 and WT5400 are all powered by the Qualcomm® QCM4490 processor and Qualcomm® QCS4490 processor which provide long lifecycles and more processing power compared to previous generations. These devices can run multiple applications including apps powered by augmented reality and AI, apps designed for voice and line of business as well as simple ‘green screen’ legacy apps."We are excited to be a part of the next evolution of Zebra’s TC5Xe series and new WT6400 and WT5400 wearable computers," said Art Miller, Vice President, Business Development & Global Head of Retail IoT, Qualcomm Technologies, Inc. "Our collaboration with Zebra equips front-line workers with intelligent computing, enabling them to be more efficient and more productive."Beyond its new wearables and mobile computers, Zebra will also showcase its recently launched MC9400 series, the ultra-rugged mobile computer designed to enhance workflow efficiency and device security across the retail, warehouse, manufacturing, and transportation and logistics industries.Intelligent Automation Advances New Ways of WorkingAutomation is a top technology-led priority for manufacturing leaders, and augmenting front-line workers is key. Zebra will unveil enhancements to the Fetch100 autonomous mobile robots (AMR) at MODEX including the Fetch100 Roller Guide Autonomous Mobile Robot which combines simplified worker-robot collaboration and conveyer delivery into one solution. Workers can easily see tasks, destinations and status via the Roller Guide’s integrated touchscreen and smart LEDs. Its ability to autonomously load and unload totes and bins from existing mechanized equipment - such as conveyors - increases worker productivity.Together with its channel partners, Zebra will also demonstrate several machine vision-based solutions at the show. These flexible, "ready solutions" enable businesses to do everything from simple track-and-trace operations to complex quality inspection checks to deep-learning-based optical character reading (DL-OCR) of manufacturing work in process. Scan tunnel, dock door and packing bench demos will highlight the efficacy of Zebra’s fixed industrial scanner and machine vision technology in reducing errors as well as improving productivity, visibility and overall operational efficiency.Zebra executives and industry thought leaders will participate in two speaking sessions including:Proximity: How Just-in-Time Everything Transforms Business, Society, and Our Lives, presented by Tom Bianculli, Chief Technology Officer, Zebra Technologies, and Professor Robert C. Wolcott, Co-Author of Proximity, How Coming Breakthroughs in Just-in-Time Transform Business, Society and Daily Life. Tuesday, March 12, at 12:45 pm – 1:30 pm, Theater H. Listen to this podcast to learn more about this session.Making Modern Warehousing a Reality, presented by Andre Luecht, Global Strategy Lead, Transport, Logistics and Warehousing, Zebra Technologies. Wednesday, March 13, at 11:15 am – 12:00 noon, Theater H.KEY TAKEAWAYSAt MODEX 2024, Zebra Technologies will introduce new solutions that enable front-line workers to be better connected and advance intelligent automation.Zebra helps businesses work in new ways to drive the right outcomes in their operations and build an agile supply chain through better accuracy, visibility, and efficiency.Visit Booth B6623 at MODEX 2024, Georgia World Congress Center – Hall B, March 11 -14 in Atlanta, Ga.ABOUT ZEBRA TECHNOLOGIESZebra (NASDAQ: ZBRA) helps organizations monitor, anticipate, and accelerate workflows by empowering their frontline and ensuring that everyone and everything is visible, connected and fully optimized. Our award-winning portfolio spans software to innovations in robotics, machine vision, automation and digital decisioning, all backed by a +50-year legacy in scanning, track-and-trace and mobile computing solutions. With an ecosystem of 10,000 partners across more than 100 countries, Zebra’s customers include over 80% of the Fortune 500. Newsweek recently recognized Zebra as one of America’s Most Loved Workplaces and Greatest Workplaces for Diversity, and we are on Fast Company’s list of the Best Workplaces for Innovators. Learn more at www.zebra.com or sign up for news alerts. Follow Zebra’s Your Edge blog, LinkedIn, Twitter and Facebook, and check out our Story Hub: Zebra Perspectives.ZEBRA and the stylized Zebra head are trademarks of Zebra Technologies Corp., registered in many jurisdictions worldwide. Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated. Qualcomm is a trademark or registered trademark of Qualcomm Incorporated. All other trademarks are the property of their respective owners. ©2024 Zebra Technologies Corp. and/or its affiliates.View source version on businesswire.com: https://www.businesswire.com/news/home/20240311280396/en/ContactsMedia Contact: Michael GilhoolyZebra Technologies+1-708-814-5281michael.gilhooly@zebra.com Industry Analyst Contact:Kasia FahmyZebra Technologies+1-224-306-8654k.fahmy@zebra.com

Business Wire

Zebra Technologies Introduces Automation Solutions at MODEX 2024 to Empower Connected Workers

https://finance.yahoo.com/news/zebra-technologies-introduces-automation-solutions-120000323.html

6b558f11-0b02-3948-9c27-585725231275

ZION

(Adds background on the sector from paragraph 3 onwards)Feb 23 (Reuters) - Zions Bancorporation said on Friday that veteran Scott Anderson was set to retire after serving as president and CEO of Zions Bank for more than 25 years, amid renewed uncertainty over the health of the U.S. regional banking sector.Anderson came to Zions 33 years ago from a "prominent role" at Bank of America, Zions Bancorporation CEO Harris Simmons said in a statement.Zions was one of the lenders in focus last year after the collapse of Silicon Valley Bank and Signature Bank roiled the regional banking sector in the United States, as spooked customers moved their money to bigger financial institutions.Utah-based Zions' shares closed about 11% down in 2023 and it is also down 11% year-to-date.Fears about the health of the industry resurfaced after New York Community Bancorpreported a surprise lossdue to higher provisions, stoking a stock rout earlier this year. The lender is down about 56% year-to-date.New York Community Bancorp named banking veteran and turnaround expertAlessandro DiNelloexecutive chair earlier this month, putting the brakes on the frenzied selloff.The U.S. Federal Reserve maintaining a high interest-rate environment to rein in inflation has weighed on regional banks' loan profits as well as the value of the securities they hold.Paul Burdiss, Zions Bancorporation's executive vice president and chief financial officer since 2015, will succeed Anderson, who is to retire on April 1.Burdiss's role will be taken over by Ryan Richards, currently corporate controller at the company. (Reporting by Pritam Biswas in Bengaluru; Editing by Pooja Desai)

Reuters

UPDATE 2-Zions Bancorporation says veteran Scott Anderson to retire

https://finance.yahoo.com/news/1-zions-bancorporation-says-veteran-215948561.html

505a755b-9f11-3df9-8394-1a933c1dbc94

ZION

Zions Bancorporation National Association (NASDAQ:ZION) Full Year 2023 ResultsKey Financial ResultsRevenue: US$2.98b (down 1.6% from FY 2022).Net income: US$648.0m (down 26% from FY 2022).Profit margin: 22% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.EPS: US$4.39 (down from US$5.80 in FY 2022).ZION Banking Performance IndicatorsNet interest margin (NIM): 3.02% (down from 3.06% in FY 2022).Cost-to-income ratio: 62.9% (up from 58.8% in FY 2022).Non-performing loans: 0.39% (up from 0.27% in FY 2022).earnings-and-revenue-growthAll figures shown in the chart above are for the trailing 12 month (TTM) periodZions Bancorporation National Association EPS Misses ExpectationsRevenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.8%.Looking ahead, revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Banks industry in the US.Performance of the American Banks industry.The company's shares are down 4.0% from a week ago.Risk AnalysisDon't forget that there may still be risks. For instance, we've identified 1 warning sign for Zions Bancorporation National Association that you should be aware of.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Zions Bancorporation National Association Full Year 2023 Earnings: EPS Misses Expectations

https://finance.yahoo.com/news/zions-bancorporation-national-association-full-121348698.html

08b00813-1f88-3d76-9ee7-00d9537f5498

ZION

In this article, we discuss 12 most undervalued bank stocks to buy. If you want to skip our discussion on the banking industry, head over to 5 Most Undervalued Bank Stocks To Buy According To Analysts. The US banking industry, having experienced stability after setbacks in March and April 2023, is anticipated to perform well in 2024, according to S&P Global. While challenges like potential deposit declines, funding cost pressures, unrealized losses, commercial real estate exposures, and economic uncertainty persist, banks are expected to build capital. Regulatory changes proposed last year in terms of capital and resolution requirements may be finalized in 2024. The Federal Reserve's decision to maintain rates initially before considering cuts in mid-2024 is expected to result in a modest decline in deposits and incremental rises in funding costs in the first half of the year. Despite a dip in profitability, banks are projected to maintain good financial health, generating a return on common equity of 10%-11% and building capital through earnings retention. Although net interest income may decrease, asset quality pressure is anticipated to rise but remain manageable, given banks' pre-provision earnings positioning them well to absorb potential credit losses.Around June 2024, banks are expected to adopt a cautious approach as the presidential election unfolds, potentially introducing new policies and regulations. With elevated interest rates and low stock prices, there is an increase in fund and deposit costs, putting pressure on bank earnings. The M&A market has significantly slowed down, but there are factors such as deposit flight, net interest margin growth, digital transformation, new product introductions, and geographic expansion plans that could fuel robust M&A activity. If an interest rate cut occurs in the 1st or 2nd quarter of 2024 and gains regulatory approval, the industry may witness a surge in M&A activity, as per KPMG. Story continuesThe IMF anticipates a decline in global inflation to 5.2% in 2024, down from its peak of 8.7% in 2022. Despite signs of deceleration in the labor market and consumer spending in countries like the United States, inflation is predicted to remain above target rates globally. Central banks worldwide are expected to fine-tune their monetary policies in 2024. In the US, the federal funds rate is projected to stay elevated, potentially dropping in the second half of the year. The European Central Bank is expected to begin reducing interest rates, while the Bank of England and the Bank of Canada are expected to lower policy rates. The Bank of Japan, maintaining a near-zero policy rate, plans adjustments to its bond yield curve control schemes. However, overall, central banks' quantitative tightening measures are set to contract the global money supply, with the United States experiencing a notable decline in money supply, reminiscent of the 1930s.Moreover, digital transformation remains a key focus for the banking sector, with ongoing investments directed towards enhancing customer service and updating technology platforms. In 2024, banks will persist in their efforts to make products digitally accessible and user-friendly, aiming to retain existing customers and attract new ones. Generative AI is gradually finding its place in banking, contributing to activities such as loan underwriting, risk forecasting, and providing personalized recommendations in customer service. According to IBM, in the realm of generative AI adoption among banking organizations, a substantial 86% are either in production or gearing up for implementation. Notably, 8% are employing a systematic approach, encompassing domains like client engagement, risk and compliance, information technology, and support functions. The majority, constituting 60%, primarily operate in advanced and emerging economies. Conversely, 14% of organizations currently have no immediate plans to engage with generative AI. Among the 78% of organizations taking a tactical approach, there is a focus on a limited number of use cases or domains, with a notable emphasis on risk and compliance and client engagement.Some of the best banking stocks favored by elite hedge funds include JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), and Citigroup Inc. (NYSE:C). However, we discuss the most undervalued stocks in the banking sector in this article. Our MethodologyFor this article, we used a stock screener and shortlisted the most undervalued stocks in the banking sector by their PE ratios, which were under 15. The most undervalued stocks according to analysts were chosen by considering their upside potential, relying on analyst price targets as of March 4. Price targets were taken from Yahoo Finance. We have also assessed the hedge fund sentiment from Insider Monkey’s database of 933 elite hedge funds tracked as of the end of the fourth quarter of 2023. The list is arranged in ascending order of the number of hedge fund holders in each firm. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here).12 Most Undervalued Bank Stocks To Buy According To AnalystsA city skyline with multiple regional banks in the foreground.Most Undervalued Bank Stocks To Buy According To Analysts12. KB Financial Group Inc. (NYSE:KB)Number of Hedge Fund Holders: 15PE Ratio as of March 4: 5.99Average Upside Potential: 23.54%Average Analyst Price Target: $63.85KB Financial Group Inc. (NYSE:KB) is a South Korean financial institution that provides a wide range of banking and financial services worldwide. The company operates through Retail Banking, Corporate Banking, Other Banking, Credit Card, Securities, Life Insurance, and Non-Life Insurance segments. It is one of the most undervalued stocks to monitor. On February 7, KB Financial Group Inc. (NYSE:KB) reported a net profit of WON 4,631.9 billion and a revenue of WON 12141.7 billion for full-year 2023. According to Insider Monkey’s fourth quarter database, 15 hedge funds were bullish on KB Financial Group Inc. (NYSE:KB), compared to 12 funds in the last quarter. William B. Gray’s Orbis Investment Management is the leading stakeholder of the company, with 850,086 shares worth over $35 million. Like JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), and Citigroup Inc. (NYSE:C), KB Financial Group Inc. (NYSE:KB) is one of the best banking stocks. 11. The Bank of N.T. Butterfield & Son Limited (NYSE:NTB)Number of Hedge Fund Holders: 16PE Ratio as of March 4: 6.55Average Upside Potential: 17.25%Average Analyst Price Target: $35.20The Bank of N.T. Butterfield & Son Limited (NYSE:NTB) ranks 11th on our list of the most undervalued stocks in the banking space. The company provides a diverse range of community, commercial, and private banking services to individuals and small to medium-sized businesses. On February 13, The Bank of N.T. Butterfield & Son Limited (NYSE:NTB) declared a $0.44 per share quarterly dividend, in line with previous. The dividend is payable on March 11, to shareholders on record as of February 26. According to Insider Monkey’s fourth quarter database, 16 hedge funds were bullish on The Bank of N.T. Butterfield & Son Limited (NYSE:NTB), compared to 12 funds in the prior quarter. Phill Gross and Robert Atchinson’s Adage Capital Management is the leading stakeholder of the company, with 1.76 million shares worth $56.6 million. 10. Prosperity Bancshares, Inc. (NYSE:PB)Number of Hedge Fund Holders: 17PE Ratio as of March 4: 13.92Average Upside Potential: 15.46%Average Analyst Price Target: $72.50 Prosperity Bancshares, Inc. (NYSE:PB) serves as the bank holding company for Prosperity Bank, offering a range of financial products and services to businesses and consumers. It is one of the most undervalued stocks to monitor. On January 17, Prosperity Bancshares, Inc. (NYSE:PB) declared a $0.56 per share quarterly dividend, in line with previous. The dividend is payable on April 1, to shareholders on record as of March 15. According to Insider Monkey’s fourth quarter database, 17 hedge funds were bullish on Prosperity Bancshares, Inc. (NYSE:PB), compared to 16 funds in the prior quarter. Brandon Haley’s Holocene Advisors is the leading stakeholder of the company, with 1 million shares worth $68.5 million. 9. Zions Bancorporation, National Association (NASDAQ:ZION)Number of Hedge Fund Holders: 19PE Ratio as of March 4: 9.06Average Upside Potential: 15.6% Average Analyst Price Target: $45.58Zions Bancorporation, National Association (NASDAQ:ZION) operates across several states, including Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company provides a range of banking services to businesses and consumers. Zions Bancorporation, National Association (NASDAQ:ZION) is one of the most undervalued stocks to watch. The company paid a $0.41 per share quarterly dividend on February 22 and the board also authorized an up to $35 million share buyback program in the beginning of February.According to Insider Monkey’s fourth quarter database, 19 hedge funds were bullish on Zions Bancorporation, National Association (NASDAQ:ZION), compared to 23 funds in the prior quarter. John Overdeck and David Siegel’s Two Sigma Advisors is the leading stakeholder of the company, with 1.90 million shares worth $83.4 million. FMI made the following comment about Zions Bancorporation, National Association (NASDAQ:ZION) in its Q1 2023 investor letter:“Our two most impacted holdings during this recent crisis were Zions Bancorporation, National Association (NASDAQ:ZION) and discount broker Charles Schwab. We believe both have sticky deposit bases, best-in-class management teams, conservative balance sheets, and attractive valuations. In both cases, outside of absolute contagion/panic resulting in a run on their deposits (a very low probability tail risk), we view the impact on the businesses as more of an “earnings” event, not a “balance sheet” event. Zions and Schwab got caught up in the contagious fear around SVB’s collapse due to some optical similarities between their balance sheets (namely bonds carried at mark-to-market losses), and Zions being a West Coast regional bank. We believe the similarities largely end there. Zions has a much more diverse deposit base than SVB. We estimate that half of Zions’ deposit base are small and medium-sized business operating deposits, which have historically been quite stable and a competitive advantage. Nearly half of Zions’ deposits are FDIC-insured, and the bank has ample liquidity to meet outflows without selling its securities portfolio. Similarly, Schwab’s retail deposit base is very sticky. Over 80% of their customers’ cash is FDIC-insured, and the cash is spread across approximately 34 million brokerage accounts (average ~$10,000 in bank cash per account). Schwab has more balance sheet liquidity than deposits. In both cases, there appears to be a low risk of correlation among their respective client bases. Although there will likely be some profit headwinds that stem from this crisis, we viewed the large declines in these shares as overly punitive, and thus believe the risk/reward for each is increasingly attractive. We have added to both positions.”8. Old National Bancorp (NASDAQ:ONB)Number of Hedge Fund Holders: 19PE Ratio as of March 4: 8.45Average Upside Potential: 18.90%Average Analyst Price Target: $19.50Old National Bancorp (NASDAQ:ONB) is next on our list of the most undervalued stocks in the banking sector. It is a bank holding company for Old National Bank, offering a variety of financial services to individual and commercial customers in the United States. On February 22, Old National Bancorp (NASDAQ:ONB) declared a quarterly dividend of $0.14 per share, in line with previous. The dividend is payable on March 15, to shareholders on record as of March 5. The company’s board also authorized a stock buyback initiative with a cap of $200 million, in effect until February 28, 2025.According to Insider Monkey’s fourth quarter database, 19 hedge funds were bullish on Old National Bancorp (NASDAQ:ONB), compared to 20 funds in the last quarter. Ken Griffin’s Citadel Investment Group is the biggest stakeholder of the company, with 3.94 million shares worth $66.7 million. 7. Pinnacle Financial Partners, Inc. (NASDAQ:PNFP)Number of Hedge Fund Holders: 20PE Ratio as of March 4: 11.40Average Upside Potential: 18.52%Average Analyst Price Target: $96.50Pinnacle Financial Partners, Inc. (NASDAQ:PNFP) is a bank holding company for Pinnacle Bank, offering diverse banking products and services to individuals, businesses, and professional entities in the United States. It is one of the most undervalued stocks to buy. On January 16, Pinnacle Financial Partners, Inc. (NASDAQ:PNFP) announced a Q4 non-GAAP EPS of $1.68, beating market estimates by $0.01. However, the revenue came in at $396.34 million, missing Wall Street consensus by $20.03 million. According to Insider Monkey’s fourth quarter database, 20 hedge funds were long Pinnacle Financial Partners, Inc. (NASDAQ:PNFP), compared to 23 funds in the prior quarter. James Hanna’s North Reef Capital is the largest stakeholder of the company, with 1.64 million shares worth $143 million. Gator Capital Management made the following comment about Pinnacle Financial Partners, Inc. (NASDAQ:PNFP) in its first quarter 2023 investor letter:“A second but higher risk opportunity is in select regional banks. Coming into March, regional banks were already at the low end of their long-term valuation range. In March, the regional bank index declined 29%, and many well-run regional banks declined more than the index. We admit there are many new negatives for regional banks in the aftermath of the Bank Crisis. Still, we think they have become too cheap and have the potential to outperform as we get clarity on the going forward business model.We see four new negatives for regional banks: 1) uninsured deposits will decline unless deposit insurance limits are increased, 2) banks will operate with higher liquidity going forward, 3) deposit repricing is accelerating, and 4) regulatory uncertainty is high.Despite these four new negative issues for banks, we believe regional bank stock prices have overshot to the downside. We estimate these four issues will cause a 10% decline in earnings, which is not bad compared to a 30% decline in stock prices. We believe the banks will be able to overcome some of these negatives with wider spreads on loans going forward. We believe we must focus on the best management teams that have shown the ability to grow while maintaining discipline on expenses.Some banks we have identified include Axos Financial, United Missouri Bank, Webster Financial, and Pinnacle Financial Partners, Inc. (NASDAQ:PNFP). These banks are strong performers and don’t have the same problems that SIVB and others had with their bond portfolios. These banks have strong deposit franchises and have posted strong loan growth for many years. We believe they will be able to balance the demands of the new banking environment and post strong results.”6. Western Alliance Bancorporation (NYSE:WAL)Number of Hedge Fund Holders: 33PE Ratio as of March 4: 8.62Average Upside Potential: 35.26%Average Analyst Price Target: $76.29Western Alliance Bancorporation (NYSE:WAL) ranks 6th on our list of the most undervalued stocks in the banking industry. It is a bank holding company for Western Alliance Bank, operating mainly in Arizona, California, and Nevada. The company's three segments are Commercial, Consumer Related, and Corporate & Other. Western Alliance Bancorporation (NYSE:WAL) paid a $0.37 per share quarterly dividend on March 1. According to Insider Monkey’s fourth quarter database, 33 hedge funds were long Western Alliance Bancorporation (NYSE:WAL), compared to 36 funds in the last quarter. Ken Griffin’s Citadel Investment Group is the leading stakeholder of the company, with 2.5 million shares worth $167.5 million. In addition to JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), and Citigroup Inc. (NYSE:C), Western Alliance Bancorporation (NYSE:WAL) is one of the best banking stocks to invest in. Miller Value Deep Value Select Strategy stated the following regarding Western Alliance Bancorporation (NYSE:WAL) in its fourth quarter 2023 investor letter:“During the quarter, our largest positive contributor was Western Alliance Bancorporation (NYSE:WAL), whose market price was up more than 40%. Western is a leading national commercial bank with a capital-light business model. The company appears to me to be positioned for long-term growth at the high end of their peer group. WAL has industry-leading underwriting (as evidenced by their low loss rate) and return on assets, which, in my view, support their 18-20% target return on common tangible equity target. Consensus expectations remain in the 15% range potentially providing a nice ongoing variant. Western’s mortgage business is also a “hidden asset” not being sufficiently recognized in the company’s current share price in my opinion. At more than 10% of their company revenue and near trough profitability, any future recovery in the mortgage market from lower interest rates could provide greater future earnings power. WAL’s shares remain attractively priced with a price-to-estimated earnings ratio (FY2) below 7x, a 40% discount to its historical long-term average and a greater than 30% discount to their banking peer group.” Click to continue reading and see 5 Most Undervalued Bank Stocks To Buy According To Analysts.  Suggested articles:13 Best Pharma Dividend Stocks To Buy in 202411 Best Consumer Electronics Stocks To Buy12 Tech Stocks To Sell Right Now According To Cathie Wood Disclosure: None. 12 Most Undervalued Bank Stocks To Buy According To Analysts is originally published on Insider Monkey.

Insider Monkey

12 Most Undervalued Bank Stocks To Buy According To Analysts

https://finance.yahoo.com/news/12-most-undervalued-bank-stocks-113241680.html

5a91bd3d-fe83-3d5b-8d4d-b49ff4ccaa3f

ZION

SALT LAKE CITY, March 8, 2024 /PRNewswire/ -- Zions Bancorporation, N.A. (NASDAQ: ZION) previously announced its earnings release schedule for the first quarter of 2024.  Zions is maintaining the date of April 22, 2024, but is revising the scheduled time from 5:30 p.m. ET to 9:30 a.m. ET. Earnings press release and presentation material will be available prior to market open.For the fiscal period             Earnings Release Conference Call Date and TimeFirst Quarter 2024                 April 22, 2024, at 9:30 a.m. ET (7:30 a.m. MT)Forward looking and other material information may be discussed on these conference calls.Media representatives, analysts and the public are invited to listen to the conference call.  Approximately three weeks prior to the calls, information on how to access these calls is expected to be published on the company's website at zionsbancorporation.com.  The webcast is expected to be archived and available for 30 days after the call is completed.Zions Bancorporation, N.A. is one of the nation's premier financial services companies with 2023 net revenue of $3.1 billion and approximately $87 billion of total assets. Founded in 1873, Zions operates under local management teams and distinct brands in 11 western states: Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The Bank is a consistent recipient of national and state-wide customer survey awards in small and middle-market banking, as well as a leader in public finance advisory services and Small Business Administration lending. In addition, Zions is included in the S&P 400 Mid-Cap and NASDAQ Financial 100 indices. Investor information and links to local banking brands can be accessed at zionsbancorporation.com.CisionView original content:https://www.prnewswire.com/news-releases/zions-bancorporation-revises-time-for-2024-q1-earnings-release-302084214.htmlSOURCE Zions Bancorporation

PR Newswire

ZIONS BANCORPORATION REVISES TIME FOR 2024 Q1 EARNINGS RELEASE

https://finance.yahoo.com/news/zions-bancorporation-revises-time-2024-160000139.html

aa535bab-6162-3db4-a600-50fdac609bad

ZTS

In this article, we will be navigating through the 16 best dog breeds for first time owners. If you wish to skip our detailed analysis, you can move directly to the 5 Best Dog Breeds For First Time Owners.Adopting or owning a pet has gained massive popularity over the years. According to a 2023 survey by the American Pet Products Association, almost 66% or 86.9 million of the households in the US own a pet. Dogs are the most popular pet choice in the US with 65.1 million out of the 86.9 million households owning a dog. In 2022, the overall spending on pet care in the US amounted to a staggering $136.8 billion. Pet ownership is popular across generations. Millennials have the highest pet ownership in the US and make up 33% of all pet owners. Gen X has the second highest number making up 25% of pet owners. You can also check out the 20 Most Popular Pets In The US.The Pet Care Industry: An OverviewAccording to a report by Grand View Research, the global pet care market was valued at $159.10 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030. The global pet care industry is predicted to reach $236.16 billion by 2030. The humanization of pets has led owners to take prompt measures to ensure that their pets are getting optimal care. The increased consumer spending on pet care products is expected to significantly contribute to the market growth during the forecasted period.Pet care services including veterinary service delivery are evolving with technological advancements and the increasing demand. Pet owners are conscious of the health of their beloved pets and are willing to invest as much as possible. The integration of technology with pet care has led to the emergence of platforms like Parker & Ace by Redesign Health. Parker & Ace is a membership-based clinic that offers members unlimited in-person and online consultations. The platform also has a 24/7 virtual care pharmacy. For an annual fee, the member pet owners can easily access the services being offered regardless of time and distance from the location of the clinic. The tech interface facilitates scheduling, accessing medical records, and setting up virtual consultations.Story continuesProminent Companies In The Pet Care IndustryChewy, Inc. (NYSE:CHWY), Petco Health and Wellness Company, Inc. (NASDAQ:WOOF), and Zoetis Inc. (NYSE:ZTS) are some of the most prominent names in the pet care industry.Chewy, Inc. (NYSE:CHWY) is an American based in Plantation, Florida. The company manufactures and offers a variety of pet care products including treats, supplies, and medications. On December 14, 2023, Chewy, Inc. (NYSE:CHWY) announced the launch of Chewy Vet Care. Chewy Vet Care will offer a variety of services including routine appointments, urgent care, and surgery. The services provided by the Chewy Vet Care is powered by Chewy's technology platform. The addition of Chewy Vet Care expands Chewy's existing portfolio of pet health offerings by incorporating services including tele-triage, insurance plans, eCommerce, and customer service.Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) was founded in 1965 and operates more than 1,500 Petco locations across the United States. The company offers a variety of pet health services, including veterinary care, grooming, and training. On January 23, Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) announced the launch of a customizable pet health insurance on petco.com. The insurance offers coverage for a variety of veterinary services including accidents and illnesses. The insurance plans start at $16 per month for dogs and $9 per month for cats. The enrolled members will receive a 10% discount on veterinary services at Petco's network of hospitals and vaccination clinics.Zoetis Inc. (NYSE:ZTS) is a notable company in the pet care industry that is headquartered in New Jersey, US. On February 13, Zoetis Inc. (NYSE:ZTS) reported earnings for the fiscal fourth quarter of 2023. The company reported an EPS of $1.24. The company's revenue for the quarter grew by 8.48% and amounted to $2.21 billion, ahead of market consensus by $21.29 million. Here are some comments from the company's earnings call:  "We delivered 7% operational revenue growth, growing faster than the industry, propelled by steady demand for innovative products that enable our customers and the animals they care for to thrive. With the ongoing momentum of our monoclonal antibodies for osteoarthritis or OA pain, we saw segment growth of 6% of the US and 9% operational growth internationally. Our companion animal portfolio remains a key growth driver, up 8% operationally, and we saw a return to growth for our livestock portfolio, up 6% operationally. While we continue to operate in an environment of global uncertainty, our diversity across markets, species, and therapeutic areas, has sustained our performance, further demonstrating that animal health is a durable, essential, and growing industry."Choosing a pet for the first time can be a daunting experience. There is a large number of dog breeds to choose from each having distinct characteristics. We have made a list of the best dog breeds for first time owners. You can also read the 15 Highest Quality Dog Food Brands To Keep Your Pup Happy and Healthy.16 Best Dog Breeds For First Time Owners16 Best Dog Breeds For First Time OwnersOur Methodology:To make a list of the best dog breeds for first time owners, we employed a consensus methodology. We consulted four different sources that listed the best dog breeds for first time owners and extracted the names that appeared in 2 of the 4 sources. Our sources included the World Animal Foundation, Reader's Digest, Daily Paws, and Spruce Pets. We then tabulated the names of breeds extracted from these sources along with the average ranking for each name. The list has been arranged initially by the number of mentions in ascending order and then by average ranking across sources in descending order.By the way, Insider Monkey is an investing website that tracks the movements of corporate insiders and hedge funds. By using a consensus approach, we identify the best stock picks of more than 900 hedge funds investing in US stocks. The top 10 consensus stock picks of hedge funds outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). Whether you are a beginner investor or a professional one looking for the best stocks to buy, you can benefit from the wisdom of hedge funds and corporate insiders.16 Best Dog Breeds For First Time Owners16. Mixed breedsNumber of Mention: 2Average Ranking Across Sources: 12Mixed breed dogs are also known as mutts or hybrids. The diverse set of genetic makeup of mixed-breed dogs makes them a good fit for first-time owners as they have a mixture of different characteristics in one dog. The genetic makeup of mixed-breed dogs adds health and longevity while enabling the owner to give a loving home to a dog that would have otherwise gone unnoticed.15. Welsh Springer SpanielNumber of Mention: 2Average Ranking Across Sources: 10Welsh springer spaniel is one of the best dog breeds for first-time owners. The small dog only has a maximum weight of approximately 45 pounds. The dog breed is very affectionate and loyal being the perfect pet to welcome in your home.14. GoldendoodleNumber of Mention: 2Average Ranking Across Sources: 8Goldendoodle is a crossbreed dog that is a hybrid of a Golden Retriever and a Poodle. The dog breed is very friendly and active. Goldendoodles are considered to have a non-shedding coat, which adds in their charm for first time dog owners.13. BeagleNumber of Mention: 2Average Ranking Across Sources: 6.5The Beagle is a small to medium-sized breed of hound. Beagles have a weight range of 20 to 30 pounds and are 13 to 15 inches tall. The dog breed has a medium-sized coat and an amazing sense of smell.12. BoxerNumber of Mention: 2Average Ranking Across Sources: 2.5The boxer is a medium size dog breed. The distinguishing characteristic of this dog breed is its muscular and athletic build. Boxer breed dogs are considered super smart and affectionate, making them a good choice for first time dog owners.11. Yorkshire TerrierNumber of Mention: 3Average Ranking Across Sources: 12The Yorkshire Terrier is also known as a Yorkie and one of the best dog breeds for first time owners. Yorkshire Terriers are a small breed of dogs and only have a maximum weight of 7 pounds. The coat of Yorkshire terriers is tan on the head and dark steel-grey on the body.10. Great DaneNumber of Mention: 3Average Ranking Across Sources: 9.7The Great Dane is a German breed of dog. The dog breed is large and can weigh up to 175 pounds. The short-furred Great Dane breed dogs have a variety of colors. Great Dane is one of the best dog breeds for first time dog owners.9. WhippetNumber of Mention: 3Average Ranking Across Sources: 9The Whippet is a British breed of medium-sized sighthound and typically weighs between 25–40 pounds. The dog breed is very agile and has a friendly nature. Whippets are also considered easy to train making them a good choice for first time owners.8. Standard PoodleNumber of Mention: 3Average Ranking Across Sources: 8Standard Poodle is one of the most popular dog breeds. Standard poodles have an average height of almost 15 inches and weigh between 40–70 pounds. Standard poodles are considered obedient and friendly.7. Labrador RetrieverNumber of Mention: 3Average Ranking Across Sources: 7Labrador retrievers are extremely friendly and are one of the smartest dog breeds. They fall in the medium-to-large category of dogs according to size. This breed of dog is a good choice when choosing a companion. Labrador retrievers also have an easy-to-maintain coat, making them a good choice for dog owners learning to take care of their new pet.6. Shih TzuNumber of Mention: 3Average Ranking Across Sources: 6.7The Shih Tzu is a small and playful dog breed. The thick and long coat is a distinguishing factor for this dog breed. Shih Tzus generally has a maximum height of 10.5 inches and weighs around 9 to 17 pounds.Click to continue reading and see 5 Best Dog Breeds For First Time Owners.Suggested articles:Top 15 Countries for Dental Tourism15 Countries with the Best Healthcare in Europe15 Countries with Highest Economic Mobility in the WorldDisclosure: None. 16 Best Dog Breeds For First Time Owners is originally published on Insider Monkey.

Insider Monkey

16 Best Dog Breeds For First Time Owners

https://finance.yahoo.com/news/16-best-dog-breeds-first-174307523.html

e67be218-7358-3831-9e0e-bca1c26bf108

ZTS

Pet owners all across America would more likely than not do anything for their pets, including shell out hundreds — if not thousands — in dollars to cover potential medical bills due to a pet-related emergency. Some of those bills can certainly rack up, and, if not properly prepared, could leave pet owners in serious debt.NerdWallet Personal Finance Expert Kimberly Palmer joins Yahoo Finance to discuss how pet owners can avoid falling into debt over hefty vet bills and animal care costs.Palmer shares insights into the affordability of pet insurance plans:"What's important to know is that you can often buy pet insurance at a relatively affordable price. So, for example, the average cost for pet insurance for a dog is about $53 a month. It's important to know, though, and this is something that surprises a lot of pet owners, the price of your pet insurance actually goes up as your pet ages. And at the same time, because of inflation, we're seeing the price of pet insurance go up anyway... But it is definitely more affordable than if you suddenly have to pay for these unexpected medical bills because your pet does either get injured or needs some kind of medical care. "For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.Editor's note: This article was written by Nicholas JacobinoVideo Transcript[AUDIO LOGO]RACHELLE AKUFFO: Would you go into debt for your furry friend? Well, a quarter of people would do just that to get life saving medical care for their pets. That's according to a NerdWallet report and a USA today survey finding 91% of dog owners have experienced financial stress over pet ownership costs. But there are ways you can keep both your pet and wallet healthy. To break it down for us, Kimberly Palmer, NerdWallet personal finance expert is here.Good to have you on the show here. It does seem like a lot of people underestimate just how much some of these health related costs for pets can really run you at a time when people can barely afford to prepare for a $250 emergency. What do people need to know about this?Story continuesKIMBERLY PALMER: What's really hard about pet care is that you really don't know what to expect, you don't whether your pet will become sick or injured. And the time to buy pet insurance, which can help you manage those costs is well before your pet needs it.And so it's really important for people to consider, what do you expect? Do you want to be able to turn to pet insurance, if your pet does need some medical care or do you want to pay for that yourself? And in some cases, risk even putting your own financial situation at risk. As you mentioned people are willing to do a lot for their pets, including go into debt. And that can be really challenging for pet owners.RACHELLE AKUFFO: But you think if people are willing to go into debt, why they're not take the insurance. Compare some of the costs that people could be looking at monthly if they do have insurance versus some of the costs, I know anecdotally for me my dog ate a piece of chewing gum and was allergic to it. 9,000 later, but if you don't have pet insurance, that's an upfront cost you have to bear.KIMBERLY PALMER: That is such a great example of the unexpected expenses that can really come up for pet owners. What's important to know is that you can often buy pet insurance at a relatively affordable price. So for example, the average cost for pet insurance for a dog is about $53 a month. It's important to know though and this is something that surprises a lot of pet owners.The price of your pet insurance actually goes up as your pet ages and at the same time because of inflation, we're seeing the price of pet insurance go up anyway. And so pet insurance is not cheap, but it is definitely more affordable than if you suddenly have to pay for these unexpected medical bills because your pet does either get injured or need some medical care.RACHELLE AKUFFO: As you look at some of the more expensive things that some of this pet insurance does and doesn't cover, what do people need to in case they think, I've got pet insurance I'm covered because there are some outside costs that are also in addition.KIMBERLY PALMER: There are. What's so important to know is that in general, you pay for a deductible when your pet needs care. And then the pet insurance kicks in to cover a percentage of the remaining cost. So that's why it can make it so much more manageable to handle those costs.But an important thing to know is that pet insurance generally does not cover pre-existing conditions as well as wellness care. Unless you add that on to your pet insurance, which of course, makes it more expensive. And so the tricky thing for pet owners is that if you know your pet needs some care because it already is sick for example, it's probably too late to get pet insurance at that point because of that exclusion of the pre-existing condition.So a lot for pet owners to consider.RACHELLE AKUFFO: And so then when you think about that cost versus say all the other costs that people have to take on at a time when inflation starting to moderate but still very high for some of these costs, how should people think about incorporating some of these costs. So that they're not hit with a shock if there is an emergency for their pet?KIMBERLY PALMER: That is really the important question and it's why it comes down to an individual decision. So what you want to do is weigh the risk of suddenly being faced with some big ticket items because of medical care for your pet versus pet insurance taking that out now, maybe when you first get a pet and you're evaluating what risk do I want to take on.You could set aside money on your own and budget ahead of time for those expenses that can come up or you can turn to pet insurance where you're paying a monthly fee, an annual fee. And then you can go to pet insurance if you need it when your pet needs some medical care. So it's something to weigh the pros and cons of, think about your budget and what might fit into it.What you don't want to do is to put yourself at risk and take on debt that is really hard to handle because that can lead to even more financial stress down the line.RACHELLE AKUFFO: That peace of mind premium certainly worth the cost if you're able to cover it. I appreciate you breaking that down for us. Kimberly Palmer, NerdWallet personal finance expert. I appreciate you taking the time. Have a great weekend.KIMBERLY PALMER: Thank you.

Yahoo Finance Video

Pet Debt: Avoid going into debt over emergency vet bills

https://finance.yahoo.com/video/pet-debt-avoid-going-debt-150004886.html

3ba73e6b-2a41-3fe4-a298-f2b3c3a80ba6

ZTS

Particular financial metrics have been proven to indicate market-beating potential when analyzing stocks. Three examples are businesses with consistently growing dividend payments and a low payout ratio, steady share repurchases, and a high and rising return on invested capital. Finding companies that meet these requirements creates a "stocked pond" for us to fish in.One business swimming around in this stocked pond is animal health specialist Zoetis (NYSE: ZTS). It's achieved a total return above 500% since its spin-off from Pfizer in 2013, but Zoetis has seen its share price struggle lately. It's now trading 23% below its all-time highs.Despite this drop, the company's operations have been resilient. With the human-pet bond growing stronger every year -- and the need to maintain healthy livestock always essential -- Zoetis looks poised to set new all-time highs sooner rather than later.The global leader in animal healthWith its medicines, vaccines, diagnostics, and medicated feed additives, Zoetis has over 300 product lines serving companion animals and livestock. It's home to 15 blockbuster drugs generating over $100 million in sales annually. The company operates through two business segments (with subsequent sales-by-species breakdowns):United States (53% of sales in 2023): Dogs and cats account for 73% of sales, with cattle adding 16%, horses 4%, poultry 4%, and swine rounding things out with 3%.International (46%): Dogs and cats equal 49% of revenue, while the remainder comes from cattle (20%), swine (11%), poultry (9%), fish (6%), horses (3%), and sheep (2%).Zoetis is a well-diversified powerhouse, holding the No. 1 market position in North America, Latin America, and Asia, alongside the No. 2 spot in Eastern and Western Europe. Despite this market share leadership, the company's growth story appears far from over.Zoetis received the first U.S. Food and Drug Administration (FDA) approval for its monoclonal antibody drugs to treat osteoarthritis (OA) in cats in 2022 and dogs in 2023. This is a significant step-change over giving nonsteroidal anti-inflammatory drugs (NSAIDs) to pets. These new treatments could eliminate a lot of pain felt by our furry friends.Story continuesIn the U.S., it is estimated that roughly 40% of dogs and cats show signs of OA, but most went without treatment before Zoetis' breakthrough, primarily due to the risks related to pets taking NSAIDs. Management believes these new drugs should grow to over $1 billion in annual sales at their peak, joining the company's dermatology and parasiticides offerings as $1 billion-per-year therapy areas.On top of this, Zoetis estimates that the renal, cardiology, and oncology markets for companion animals will triple in size by 2032, creating three additional growth avenues for the company's research and development team to explore.Impressive -- and improving -- profitabilityBuoyed by its leadership advantage and long list of patent-protected drugs, Zoetis has achieved top-tier profitability metrics. However, these figures are truly remarkable because they are still improving.ZTS Return on Invested Capital ChartThese steadily rising profitability metrics may indicate a widening moat for Zoetis, which appears to be expanding upon its leadership position in its market. Its return on invested capital (ROIC) is particularly noteworthy, as it highlights the company's ability to generate more net income from its debt and equity than most of its peers.With its current ROIC of 20%, Zoetis ranks in the top quintile of the S&P 500. This is important to investors. Companies in this top 20% have historically outperformed their lower-ranked peers by a wide margin since 2002.Growing cash returns to shareholdersThe company's tremendous net profit margin of 27% arms management with a stockpile of profits to return to shareholders -- and it has a long history of doing so. By buying back roughly 1% of its outstanding shares each year while growing its dividend by 26% annually over the last decade, Zoetis has handsomely rewarded its long-term shareholders.ZTS Shares Outstanding ChartS&P Global's S&P 500 Buyback Index shows the potential of share buybacks. Consisting of the 100 most buyback-heavy stocks in the S&P 500, this index has collectively outperformed the broader S&P 500 Index in 16 out of the 20 years from 2000 to 2019.Furthermore, stocks with growing dividends like Zoetis' have outperformed the S&P 500 Index by 2.5 percentage points annually since 1973. With Zoetis quintupling its dividend over the last decade yet only using 31% of its net income to fund these payments, the company should remain a dividend grower for a long time.Zoetis' stock is trading at 34 times next year's earnings, so investors should be aware that it isn't traditionally cheap. However, thanks to its three market-beating indicators and a leadership position in an industry that should only become more important with time, Zoetis makes for a perfect dollar-cost averaging opportunity.Should you invest $1,000 in Zoetis right now?Before you buy stock in Zoetis, consider this:The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zoetis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.See the 10 stocks*Stock Advisor returns as of February 20, 2024Josh Kohn-Lindquist has positions in Zoetis. The Motley Fool has positions in and recommends Pfizer, S&P Global, and Zoetis. The Motley Fool has a disclosure policy.1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now was originally published by The Motley Fool

Motley Fool

1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now

https://finance.yahoo.com/news/1-magnificent-p-500-dividend-144500022.html

671c524d-4358-3389-92b4-2f76c8026c78

ZTS

In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024. Within the healthcare industry in the US, the pharmaceutical sector has experienced significant transformations in recent times. These changes include the influence of the COVID-19 pandemic, the formation of collaborations spanning the entire value chain, and a continuously evolving regulatory landscape. The US pharmaceutical market is the largest in the world, both in terms of revenue and innovation. It plays a crucial role in global healthcare and pharmaceutical research and development. According to S&P Global Ratings, major pharmaceutical companies collectively earned around $700 billion in revenue during 2023, which includes some additional revenue sources beyond pharmaceuticals. This amount constitutes over half of the estimated $1.1 trillion global pharmaceutical market. Moreover, the US accounts for approximately 40% to 50% of the total revenues in the global pharmaceutical industry. The US market is particularly appealing to branded pharmaceutical companies due to substantially higher prices and profit margins compared to other regions.Beyond the financial returns of the pharmaceutical industry in the US, its innovation stands out on the global stage. In recent times, there have been significant advancements in vaccine development, cancer treatments, GLP-1 drugs for managing obesity, gene therapy, gene editing technology for rare diseases, and novel treatments for complex illnesses such as Alzheimer’s disease. However, despite these achievements, the sector grapples with a persistent value problem, leaving investors dissatisfied. Relative to market indices, the pharmaceutical sector continues to underperform in capital markets. The reason for this could be that in 2023, the healthcare field in the US encountered challenging circumstances, marked by persistently high inflation rates, shortages in labor, and the ongoing prevalence of COVID-19. The S&P 500 Pharmaceuticals Select Industry Index, which monitors the performance of pharmaceutical companies, showed a total return of 2.77% for the year, in contrast to the 25.4% return of the broader market. That said, it's worth noting that the pharmaceutical branch did not experience as much decline as other sectors like consumer staples and utilities.Story continuesOne significant factor contributing to the stability of the pharmaceutical area is the active pursuit by pharmaceutical companies to acquire innovative biotech firms through a series of smaller acquisitions, rather than pursuing large-scale mergers. This strategy helps them address potential gaps in their product pipelines more effectively. In a recent development, Novartis AG (NYSE:NVS) has reached an agreement to acquire MorphoSys AG (NASDAQ:MOR), a move aimed at obtaining an experimental medicine for blood cancer that complements Novartis's existing portfolio. This acquisition is among six deals valued at over $1 billion that have been announced just this year, as reported by Bloomberg.The healthcare sector's lackluster performance in 2023 hasn't dampened the enthusiasm of analysts. Healthcare investors and analysts are unexpectedly optimistic about the outlook. Although few anticipate rapid or explosive growth, and certain segments are more favorable than others, there's a prevailing sentiment that the healthcare sector as a whole is poised for a resurgence. Ziad Bakri, a portfolio manager at T. Rowe Price, discussed the outlook for the sector with Barron's this year. Here are some comments from the analyst:“Everyone worries about these stocks in election years, and I feel like we’ve [already] taken a lot of pain. Most of the sub-sectors are pretty well set up for next year.”Mr. Bakri also addressed the impact of GLP-1 weight loss medications, which triggered sell-offs in the medical devices sector. The rationale behind this was the belief that these medications would reduce the necessity for various medical procedures and devices. According to Bakri, many of these stocks have only partially recovered from their losses related to GLP-1. He anticipates that concerns regarding GLP-1 will continue to affect the stocks, but he also mentioned that there may be a growing understanding in the market that the effects will be more prolonged, particularly if interest rates decrease.Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), and Merck & Co., Inc. (NYSE:MRK) are some of the best pharma stocks because of their consistent performance and their ability to pay regular dividends to shareholders. In this article, we will further take a look at some of the best dividend stocks from the pharma sector.13 Best Pharma Dividend Stocks To Buy in 2024A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products.Our Methodology:For this list, we scanned the holding of VanEck Pharmaceutical ETF, which aims to mirror the price and yield movements of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR). This index is designed to monitor the overall performance of companies engaged in pharmaceutical activities, encompassing pharmaceutical research and development, as well as the production, marketing, and sales of pharmaceutical products. From the index, we picked 13 stocks that pay dividends and have garnered the most attention from hedge fund investors by the conclusion of Q4 2023, using data from Insider Monkey’s database. The stocks are ranked in ascending order of the number of hedge funds having stakes in them. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here).13. Organon & Co. (NYSE:OGN)Number of Hedge Fund Holders: 30Organon & Co. (NYSE:OGN) is an American pharmaceutical company that focuses on improving the health of women throughout their lives. They specialize in developing and delivering innovative solutions in women's health, including contraception, fertility, menopause management, and other related areas. On February 15, the company declared a quarterly dividend of $0.28 per share, which was in line with its previous dividend. It is one of the best dividend stocks on our list as the company has been maintaining regular dividends since 2021. The stock's dividend yield on March 4 came in at 6.37%.At the end of Q4 2023, 30 hedge funds in Insider Monkey's database reported owning stakes in Organon & Co. (NYSE:OGN), compared to 33 in the previous quarter. The total value of these stakes is over $303.6 million.12. Sanofi (NASDAQ:SNY)Number of Hedge Fund Holders: 32Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company that engages in the research, development, manufacturing, and marketing of pharmaceutical products. On February 1, the company declared a 5.6% hike in its annual dividend to €3.76 per share. Through this increase, the company stretched its dividend growth streak to 29 years, which makes SNY one of the best dividend stocks in the pharma sector. As of March 4, the stock has a dividend yield of 4.01%.The number of hedge funds tracked by Insider Monkey owning stakes in Sanofi (NASDAQ:SNY) grew to 32 in Q4 2023, from 29 in the previous quarter. The collective worth of these stakes is over $1.1 billion. With more than 14.3 billion shares, Fisher Asset Management was the company's leading stakeholder in Q4.11. GSK plc (NYSE:GSK)Number of Hedge Fund Holders: 40GSK plc (NYSE:GSK) is a leading global healthcare company. It operates across various therapeutic areas including respiratory, HIV/AIDS, oncology, immuno-inflammation, and vaccines. The company currently offers a quarterly dividend of $0.406 per share and has a dividend yield of 3.48%, as of March 4. During FY23, it returned £2.2 billion to shareholders through dividends, which makes GSK one of the best dividend stocks in the pharma sector.As of the close of Q4 2023, 40 hedge funds in Insider Monkey's database reported having stakes in GSK plc (NYSE:GSK), down from 42 in the preceding quarter. The consolidated value of these stakes is roughly $1.8 billion.10. Viatris Inc. (NASDAQ:VTRS)Number of Hedge Fund Holders: 43Viatris Inc. (NASDAQ:VTRS) is a global pharmaceutical company formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer Inc. Viatris focuses on providing affordable access to high-quality medicines, including generic drugs, complex generics, biosimilars, and over-the-counter products. The company initiated its dividend policy in 2021 and currently pays a quarterly dividend of $0.12 per share. With a dividend yield of 3.87% as of March 4, VTRS is one of the best dividend stocks on our list.According to Insider Monkey's database of Q4 2023, 43 hedge funds owned stakes in Viatris Inc. (NASDAQ:VTRS), which remained unchanged from the previous quarter. These stakes are collectively valued at over $1.2 billion. Among these hedge funds, Deerfield Management was the company's leading stakeholder in Q4.9. Cencora, Inc. (NYSE:COR)Number of Hedge Fund Holders: 48Cencora, Inc. (NYSE:COR) previously identified as AmerisourceBergen, operates as a drug wholesale business and a contract research organization based in the US. The company was a part of 48 hedge fund portfolios at the end of Q4 2023, up from 43 in the previous quarter, as per Insider Monkey's database. The stakes owned by these hedge funds have a collective value of over $1.17 billion.Cencora, Inc. (NYSE:COR), one of the best dividend stocks, has been growing its dividends for the past 19 consecutive years. The company's current quarterly dividend comes in at $0.51 per share for a dividend yield of 0.86%, as recorded on March 4.8. Zoetis Inc. (NYSE:ZTS)Number of Hedge Fund Holders: 50Zoetis Inc. (NYSE:ZTS) is an American drug company that develops, manufactures, and markets a wide range of veterinary medicines and vaccines for livestock and companion animals. On February 6, the company announced a quarterly dividend of $0.432 per share, which fell in line with its previous dividend. This was the company's 12th consecutive year of dividend growth, which places ZTS on our list of the best pharma dividend stocks to buy in 2024. The stock has a dividend yield of 0.92%, as of March 4.Insider Monkey's database of Q4 2023 indicated that 50 hedge funds owned stakes in Zoetis Inc. (NYSE:ZTS), compared with 56 in the previous quarter. The total value of these stakes is more than $1.34 billion. Cantillon Capital Management was the largest stakeholder of the company in Q4 2023.7. Bristol-Myers Squibb Company (NYSE:BMY)Number of Hedge Fund Holders: 60Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients with serious diseases, particularly in the areas of oncology, cardiovascular, immunoscience, and fibrosis. The company pays a quarterly dividend of $0.60 per share, having raised it by 5.3% in December 2023. Through this increase, it achieved its 18th annual consecutive dividend growth, which makes BMY one of the best dividend stocks in the pharma sector. As of March 4, the stock offers a dividend yield of 4.65%.At the end of December 2023, 60 hedge funds in Insider Monkey's database owned stakes in Bristol-Myers Squibb Company (NYSE:BMY), down slightly from 65 in the previous quarter. These stakes have a total value of over $2 billion.6. McKesson Corporation (NYSE:MCK)Number of Hedge Fund Holders: 69McKesson Corporation (NYSE:MCK) ranks sixth on our list of the best dividend stocks from the pharma sector. The global healthcare and pharmaceutical company has been growing its dividends for the past seven years and offers a quarterly dividend of $0.62 per share. The stock's dividend yield on March 4 came in at 0.47%.The number of hedge funds tracked by Insider Monkey holding stakes in McKesson Corporation (NYSE:MCK) jumped to 69 in Q4 2023, from 58 in the previous quarter. These stakes are collectively valued at over $4.2 billion. Click to continue reading and see 5 Best Pharma Dividend Stocks To Buy in 2024.  Suggested articles:14 Best Real Estate and Realty Stocks To Buy According to Analysts12 Best Single Digit Stocks To Invest In12 Best Battery Stocks To Invest In Before They Take OffDisclosure. None. 13 Best Pharma Dividend Stocks To Buy in 2024 is originally published on Insider Monkey.

Insider Monkey

13 Best Pharma Dividend Stocks To Buy in 2024

https://finance.yahoo.com/news/13-best-pharma-dividend-stocks-075655155.html

75b5fd54-d4f8-32c0-9750-62245383b0c2

ZTS

PARSIPPANY, N.J., March 05, 2024--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 14, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:30 a.m. ET.Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.About ZoetisAs the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.ZTS-CORZTS-IRView source version on businesswire.com: https://www.businesswire.com/news/home/20240304739185/en/ContactsMedia Contacts:Jenielle Alonso1-973-945-4333 (o)jenielle.alonso@zoetis.com Laura Panza1-973-975-5176 (o)laura.panza@zoetis.comInvestor Contacts:Steve Frank1-973-822-7141 (o)steve.frank@zoetis.com Nick Soonthornchai1-973-443-2792 (o)nick.soonthornchai@zoetis.com

Business Wire

Zoetis to Participate in the Barclays Global Healthcare Conference

https://finance.yahoo.com/news/zoetis-participate-barclays-global-healthcare-133000526.html

bd9a8b98-88e8-3ff6-90d5-b675c2ac5d77